Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Axim Biotechnologies Inc AXIM

Healthcare Biotechnology Cannabis
Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.


PINL:AXIM - Post by User

Axim Biotechnologies Inc > The next big marijuana play in the US, can we do it twice!?!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by capitalgrowthon Jan 27, 2017 12:02pm
333 Views
Post# 25763910

RE:The next big marijuana play in the US, can we do it twice!?!

RE:The next big marijuana play in the US, can we do it twice!?!
Although I wish I could've got in sooner, I was able to buy at $1.06 and sold today at $9.90 so almost as low as it went today, but oh well, we made amazing money!

I've put my earnings into Lifestyle Delivery Systems (LDS) now, I truly expect to see the same thing happen here, the Cannastrips have all the potential that Axim has and more!

Just my two cents, do your own homework, good luck everyone!


LDS ? no its happening right now with VIN (MJ Biopharma),,,they are in same space as AXIM (delivery systems) but with oils, international pattent.....


https://www.marketwired.com/press-release/vinergy-resources-ltd-announces-letter-agreement-acquisition-mj-biopharma-1099955-bc-cse-vin-2183078.htm
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities